Key points from article :
In an interview with Lifespan.io, Reason, founder and CEO of Repair Biotechnologies, described the company's lead drug candidate, REP-0004, which aims to reverse the build-up of fatty plaque in arteries that drives heart disease. The approach targets excess "free" cholesterol inside cells, which Repair Bio sees as a key driver of atherosclerosis.
The drug uses lipid nanoparticles to deliver mRNA to the liver, where it instructs cells to make proteins that break down excess cholesterol. According to the company, this sets off the body's own system for removing cholesterol from tissues, leading to plaque regression and reduced liver fibrosis and inflammation. The effect lasts only the few days the proteins are present, and the main breakdown product is cleared quickly.
Much of the interview focused on regulation. The FDA does not accept shrinking arterial plaque as a primary endpoint for approval, so Repair Bio is looking at familial hypercholesterolaemia, an inherited condition, as a first target, with exercise tolerance as the measure of benefit. The drug has received orphan drug designation, the company is applying to the FDA's new Rare Disease Evidence Principles programme, and it is now working on manufacturing and safety studies ahead of a first trial targeted for mid-2027, depending on fundraising. Reason described biotech as "basically an industry built on delay."
All of the claims about plaque regression and liver benefits come from the company, and no clinical data or peer-reviewed results were presented in the interview.


